Sera from 100 patients with SLE, 74 patients with other neurological disorders and injuries, and 60 normal controls were examined both by enzyme immunoassays and by Western immunoblotting for autoantibodies to MAP-2. This evidence concerns the gene MAP2 and nervous system disorder.